The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2- locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
 
Funan Liu
No Relationships to Disclose
 
Jifang Gong
No Relationships to Disclose
 
Zhaoyu Jin
Employment - FutureGen Biopharmaceutical
 
Miao Zhang
No Relationships to Disclose
 
Shu Zhang
No Relationships to Disclose
 
Yanqiao Zhang
No Relationships to Disclose
 
Xinjun Liang
No Relationships to Disclose
 
Yun Li
Employment - FutureGen Biopharmaceutical
 
Xiaochun Yang
Employment - FutureGen Biopharmaceutical
 
Yaping Yang
Employment - FutureGen Biopharmaceutical
 
Lin Shen
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; MSD; SERVIER; Transcenta Holding Limited
Research Funding - BeiGene (Inst)